<DOC>
	<DOCNO>NCT02241629</DOCNO>
	<brief_summary>A double-blind , randomize , placebo control , multicenter , dose-finding phaseⅡclinical superiority study .</brief_summary>
	<brief_title>Levo Phencynonate Hydrochloride Prevention Seasickness</brief_title>
	<detailed_description>The trial compose 3 part : 1 ) On-boat screen period seasickness safety test evaluate minus one day . 2 ) 4 week washout period eliminate impact voyage experience . 3 ) On-boat drug test period . The subject administer drug voyage . The seasickness symptom evaluate voyage . The safety test conduct one day on-boat testing .</detailed_description>
	<mesh_term>Motion Sickness</mesh_term>
	<criteria>Subjects fulfil diagnostic criterion motion sickness Have medical history motion sickness During screening , severity sea sickness assess moderate accord sea sickness severity scale . Adults 1855 year , male female . Agree participate study sign ICF independently . Be allergic study drug allergic constitution ALT , AST≥ 1.5 time ULN , Scr＞ULN , clinical significant lab value . Abnormal ECG clinical significant judge investigator , include : QTc＞normal range Have medical history urination disorder Have headache , vertigo , dizziness nsomnia cause disease motion sickness . Have active gastrointestinal disease overweight ( BMI≥24kg/m2 ) Have internal ear disease may disturb evaluation motion sickness . Have glaucoma posterior circulation ischemia Have anxiety , depression mental disease investigator consider inadaptable participate study . Participated study within past 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>motion sickness</keyword>
</DOC>